Identifying the Best Populations to Target, De-Risking Discovery and Early-Stage Development

1 minute read

Published: June 3rd, 2026

About This Webinar

In this session, we explore real-world use cases where AI and LLMs (Large Language Models) have been applied to explore large data sources such as omics, literature, and real-world data (RWD). We explore how AI can help identify optimal target populations, endpoints, and even support drug repurposing.

Speaker:

Billy Amzal, Ph.D.
Head of Strategic Consulting, Phastar

Key Takeaways:

  • How AI helps explore large datasets for drug development
  • De-risking clinical research using AI for precision care
  • Real-world examples of AI transforming early-stage development
Complete the form below to access the recording and slides:

Related articles

Bridging the Efficacy Effectiveness Gap in Rare Diseases with RWD

Bridging the Efficacy Effectiveness Gap in Rare Diseases with RWD

June 2nd, 2026 1 minute read

About This Webinar Drug development in rare diseases requires the most efficient use of limited data, across both cli...

Driving Clinical Research with AI: From Early Discovery to Regulatory-Grade Insights

Driving Clinical Research with AI: From Early Discovery to Regulatory-Grade Insights

May 19th, 2026 1 minute read

Join us for a transformative three-part webinar series, “Driving Clinical Research with AI,” where indust...

Causal Inference Through a Regulatory Lens

Causal Inference Through a Regulatory Lens

May 15th, 2026 1 minute read

About This Webinar As expectations for robust, real-world evidence continue to grow, understanding how regulators eva...